Which pharma CEO is least likely to keep his job?
An amazingly interesting vote is going on right now over at the WSJ Health blog. The question is which "among the leaders of the current executive pack will win the test of endurance to remain the last CEO standing?"
But of course, certain CEOs or firms can be upvoted because of loyal web followers.
So we think it is more important to find out who the losers are . . . the ones likely to be kicked out of a job, or the ones likely to be taken over. Below is the data.
At the time I'm writing this, the pharma CEO voted least likely to keep his job, by over 700 WSJ readers, is Bernard Poussot of Wyeth. He just got his job and has a reputation as an excellent executive, so perhaps this means that readers expect that Wyeth will be taken over by Pfizer, something Ms. Arnold at Credit Suisse is recommending. Of course, six months before she made her recommendation, I wrote the post "Pfizer should buy Wyeth."
Go to the WSJ for most recent results, looks like they may hit a thousand votes later today!